| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/29/2009 | US7638607 Urocortin proteins and uses thereof |
| 12/29/2009 | US7638604 Monoclonal antibodies against interleukin-22 |
| 12/29/2009 | US7638603 Use in diagnosis and treatment of cytokine disorders such as tumor metastasis, angiogenesis, cellular migration and ovulation, as well as neurogenesis |
| 12/29/2009 | US7638602 Heterodimeric human cytokine receptor comprising Zcytor16/Zcytor11 components for use in treatment of cell proliferative, inflammatory and immune disorders |
| 12/29/2009 | US7638601 Transient receptor potential channel TRPM8 and its use |
| 12/29/2009 | US7638600 identification and characterization of environmental bacteriophages infecting Bacillus anthracis, including enzymes, fusion proteins |
| 12/29/2009 | US7638599 Enhance uptake of a pharmaceutically active agent into a cell, into or out of an intracellular compartment, and across a cell layer either directly or from a pharmaceutically active agent loaded particle; drug delivery |
| 12/29/2009 | US7638598 ErbB interface peptidomimetics and methods of use thereof |
| 12/29/2009 | US7638551 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 12/29/2009 | US7638519 Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| 12/29/2009 | US7638511 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| 12/29/2009 | US7638502 Treatment of EBV and KHSV infection and associated abnormal cellular proliferation |
| 12/29/2009 | US7638499 Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| 12/29/2009 | US7638498 Substances for preventing and treating autoimmune diseases |
| 12/29/2009 | US7638497 For enhancing apoptosis and treating proliferative disorders; antitumor agents |
| 12/29/2009 | US7638495 inhibiting precipitation; bone morphogenic proteins |
| 12/29/2009 | US7638494 G-type peptides to ameliorate atherosclerosis |
| 12/29/2009 | US7638493 Phospholipid, higher alcohol, and higher aliphatic acid; free of protein and peptide; respiratory disorders |
| 12/29/2009 | US7638492 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders |
| 12/29/2009 | US7638491 Administering a polypeptide having an oxime-containing non-natural amino acid, from a translation system of: a polynucleotide comprising a selector codon encoding the polypeptide, a tRNA comprising the oxime-containing amino acid |
| 12/29/2009 | US7638490 For treating anorexia or cachexia |
| 12/29/2009 | US7638489 Modulation of angiogenesis by Bartonella henselae |
| 12/29/2009 | US7638488 Such as acarbose or castanospermine; interferons |
| 12/29/2009 | US7638487 Administering a lactoferrin composition to provide an improvement in pain, wherein pain is associated with cancer and wherein lactoferrin composition comprises an N-terminal lactoferrin variant with a deletion, substitution, or combination thereof, of from 1 to 16 N-terminal amino acid residues |
| 12/29/2009 | US7638486 administering a first peptide comprising 10 to 50 amino acid residues and a second protein selected from bone morphogenic proteins, transforming growth, epidermal growth, epithelial cell growth, fibroblast growth, platelet derived growth or insulin-like growth factors, to enhance regeneration of bones |
| 12/29/2009 | US7638485 Modulating apoptosis |
| 12/29/2009 | US7638484 Methods for accelerating wound healing by administration of adipokines |
| 12/29/2009 | US7638482 Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases |
| 12/29/2009 | US7638481 With vaccinia virus complement control protein, poxvirus encoded |
| 12/29/2009 | US7638480 Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| 12/29/2009 | US7638335 Inhibit inflammation for long periods without accompanying serious side effects in the drug therapy to patients with inflammatory bowel syndrome |
| 12/29/2009 | US7638330 Method of promoting the differentiation of staminal cells |
| 12/29/2009 | US7638327 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with expression of B-cells and immunoglobulins); treatment of cancers, lymphomas, autoimmune diseases related to B-cells |
| 12/29/2009 | US7638323 for treating or preventing hyperacute rejection; solid phase synthesis; genetic engineering |
| 12/29/2009 | US7638305 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 12/29/2009 | US7638304 Hybrid fusion protein transcription regulator to induce interferon target gene expression |
| 12/29/2009 | US7638303 Soluble ErbB3 receptor isoforms |
| 12/29/2009 | US7638302 Soluble ErbB3 receptor isoforms |
| 12/29/2009 | US7638300 In vivo incorporation of unnatural amino acids |
| 12/29/2009 | US7638283 Amyloid β protein (globular assembly and uses thereof) |
| 12/29/2009 | US7638282 Genes of an otitis media isolate of nontypeable Haemophilus influenzae |
| 12/29/2009 | US7638281 Polypeptide, cDNA encoding the same and use of them |
| 12/29/2009 | US7638277 Diagnosing ovarian cancer by detecting a TADG-12 protein in biological sample, immunoaffinity to an antibody, bioassay, immunoassay |
| 12/29/2009 | US7638272 administering a polypeptide to the cancer cells of the mammal in vivo for sensitizing the cancer cells to the therapeutic chemotherapy, radiation treatment; gene expressed polypeptide; secreted protein acidic and rich in cystein |
| 12/29/2009 | US7638149 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same |
| 12/29/2009 | US7638138 Compositions for nasal administration of pharmaceuticals |
| 12/29/2009 | US7638131 Coccidiosis poultry vaccine |
| 12/29/2009 | US7638129 Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone |
| 12/29/2009 | US7638128 Reducing apoptosis and/or tissue injury due to cardiac ischemia via exposure of tissue to mixture comprising secreted frizzled related protein (Sfrp) and a paracrine factor of a mesenchymal stem cells (MSC); tissue engineering and repair |
| 12/29/2009 | US7638127 Peptide conjugated anti-cancer prodrugs |
| 12/29/2009 | US7638126 Methods of treating pain and inflammation in neuronal tissue using antagonists of IL-31, IL31Ra and/or OSMRb |
| 12/29/2009 | US7638125 different epitopes are located within the binding domain of the natural ligand(s) of said receptor; first and second antigen-binding site binds to a different epitope on the same EGFR molecule; anticarcinogenicb antimetastasis agents |
| 12/29/2009 | US7638123 Controlling gene expression; apoptosis therapy; Continuous infusion; genetically engineered |
| 12/29/2009 | US7638073 Photochromic material comprising a proteorhodopsin apoprotein and a retinal analog |
| 12/29/2009 | US7637900 Methods of administering a material into a patient for dermal enhancement |
| 12/29/2009 | CA2464768C Method and composition for potentiating an opiate analgesic |
| 12/29/2009 | CA2446798C Solid pharmaceutical compositions comprising cyclosporin |
| 12/29/2009 | CA2429440C Dehalogeno-compounds |
| 12/29/2009 | CA2367507C Angiogenesis using three-dimensional stromal tissue constructs |
| 12/29/2009 | CA2345369C Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use |
| 12/29/2009 | CA2291087C Compositions suitable for controlled release of the hormone gnrh and its analogs |
| 12/29/2009 | CA2282720C Dolastatin-15 derivatives in combination with taxanes |
| 12/29/2009 | CA2189848C Photocleavable agents and conjugates for the detection and isolation of biomolecules |
| 12/24/2009 | US20090318934 Compressible/expandable medical graft products, and methods for applying hemostasis |
| 12/24/2009 | US20090318677 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| 12/24/2009 | US20090318665 Pharmaceutical formulations |
| 12/24/2009 | US20090318368 Angiotensin-converting enzyme inhibitory peptides |
| 12/24/2009 | US20090318367 Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs |
| 12/24/2009 | US20090318366 Cholesterol lowering protein hydrolysates |
| 12/24/2009 | US20090318365 Metastin derivatives and use thereof |
| 12/24/2009 | US20090318364 Method and peptide for regulating cellular activity |
| 12/24/2009 | US20090318363 Peptide Aptamer for Neutralizing the Binding of Platelet Antigene Specific Antibodies and Diagnostic and Therapeutic Applications Containing the Same |
| 12/24/2009 | US20090318362 Oligomeric compounds for the modulation of survivin expression |
| 12/24/2009 | US20090318361 Anti-hemorrhage medication pack |
| 12/24/2009 | US20090318360 Use of the neurotoxic component of a botulinum toxin for treating arthritis |
| 12/24/2009 | US20090318359 Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains |
| 12/24/2009 | US20090318358 Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains |
| 12/24/2009 | US20090318357 Molecules Preferentially Associated with Effector T Cells or Regulatory T Cells and Methods of Their Use |
| 12/24/2009 | US20090318356 Methods and compositions for control of fetal growth via modulation of relaxin |
| 12/24/2009 | US20090318355 Administering to one or more malignant cells an effective amount of a peptide species comprising an E-domain of insulin-like growth factor I (IGF-I); cancer |
| 12/24/2009 | US20090318354 Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1) |
| 12/24/2009 | US20090318353 Acylated Exendin-4 Compounds |
| 12/24/2009 | US20090318352 Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins |
| 12/24/2009 | US20090318351 Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
| 12/24/2009 | US20090318350 Pan-her antagonists and methods of use |
| 12/24/2009 | US20090318349 Transglutaminase variants with improved specificity |
| 12/24/2009 | US20090318348 Proteins, Nucleic Acids Encoding the Same, and Associated Methods of Use |
| 12/24/2009 | US20090318347 Novel compounds and their effects on feeding behaviour |
| 12/24/2009 | US20090318346 BIVALENT ErbB LIGAND BINDING MOLECULES AND METHODS FOR THEIR PREPARATION AND USE |
| 12/24/2009 | US20090318345 Means and methods for modulating stem cell mobilization |
| 12/24/2009 | US20090318344 Compositions and methods for modulating hemostasis using variant forms of activated factor v |
| 12/24/2009 | US20090318343 Protein Formulations for Use at Elevated Temperatures |
| 12/24/2009 | US20090318342 Compounds |
| 12/24/2009 | US20090318341 Methods of using OSK1 peptide analogs |
| 12/24/2009 | US20090318340 IL-17 homologous polypeptides and therapeutic uses thereof |
| 12/24/2009 | US20090318339 Biodegradable polymers having a pre-determined chirality |
| 12/24/2009 | US20090318338 Methods for modulating bone formation and mineralization by modulating krc activity |
| 12/24/2009 | US20090318337 Compositions and methods for activating innate and allergic immunity |
| 12/24/2009 | US20090318336 Deuterated Cyclosporine Analogs and Methods of Making the Same |
| 12/24/2009 | US20090318335 Heterodimeric Peptide Compounds Displaying Ngf Activity and Their Use to Treat Neurodegenerative Disorders |